Pfizer Up Nearly 6%, on Pace for Largest Percent Increase Since December 2021 — Data Talk
Pfizer Inc. (PFE) is currently at $27.09, up $1.47 or 5.75%
--Would be highest close since April 3, 2024, when it closed at $27.22
--On pace for largest percent increase since Dec. 15, 2021, when it rose 5.87%
--Currently up three of the past four days
--Down 5.9% year-to-date
--Down 55.77% from its all-time closing high of $61.25 on Dec. 16, 2021
--Down 29.54% from 52 weeks ago (May 3, 2023), when it closed at $38.45
--Down 32.74% from its 52-week closing high of $40.28 on June 13, 2023
--Up 7.25% from its 52-week closing low of $25.26 on April 25, 2024
--Traded as high as $27.30; highest intraday level since April 9, 2024, when it hit $27.42
--Up 6.56% at today's intraday high; largest intraday percent increase since Nov. 26, 2021, when it rose as much as 7.96%
--Sixth best performer in the S&P 500 today
--Third most active stock in the S&P 500 today
All data as of 2:07:54 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
May 01, 2024 14:24 ET (18:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact